1450 ET - CVS Health faces strong pushback from patients on its pharmacy-benefit manager's move to favor the weight-loss medication Wegovy over its rival Zepbound starting next month, UBS analysts say in a research note. Their checks of social media channels showed very high patient awareness of the upcoming changes, which would automatically give prior authorizations for Wegovy to anyone with a prior authorization for Zepbound. Appeals of this change can be made, but pricing remains unknown for successful appeals, the analysts say. Patient pushback is high; some have started a petition and have been contacting the government and employer HR departments to maintain Zepbound access, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
June 10, 2025 14:50 ET (18:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。